{"prompt": "['OSTPDL1', 'Page 39 of 60', 'Evaluations, Tests and Observations', 'Prior to', 'Studies to be Obtained', 'Baseline', 'During', 'Prior to', 'End of', 'Subsequent', 'Cycle 1', 'Cycle 2', 'Cycles', 'Therapy', 'History', 'X', 'X', 'X', 'X', 'Physical exam with vital', 'X', 'Weekly', 'X', 'X', 'X', 'signs', 'Height, weight, BSA', 'X', 'X', 'X', 'X', 'Performance status', 'X', 'X', 'X', 'X', 'CBC, diff, platelets\u00b9', 'X', 'Weekly', 'X', 'X', 'X', 'Electrolytes, including', 'X', 'X', 'X', 'X', 'CA++, PO4, Mg++1', 'BUN/creatinine\u00b9', 'X', 'X', 'X', 'X', 'ALT (SGPT), AST and total', 'X', 'X', 'X', 'X', 'bilirubin\u00b9', 'Total protein/albumin', 'X', 'X', 'X', 'X', 'Amylase, lipase, CRP', 'X', 'X', 'X', 'X', 'Pregnancy test (females\u00b2', 'X', 'X', 'X', 'X', 'Free T4 and TSH\u00b3', 'X', 'X', 'X', 'X', 'Cortisol', 'X', 'X', 'X', 'X', 'Tumor disease evaluation4', 'X', 'End of', 'End of Cycle', 'X', 'cycle 2', '4, then every', '3 cycles', 'CT Chest5', 'X', 'End of', 'End of Cycle', 'X', 'cycle 2', '4, then every', '3 months', '18F-FDG PET/PET-CT or', 'X', 'End of', 'End of Cycle', 'X', 'bone scan6', 'cycle 2', '4, then every', '3 months', 'Pulse oximetry', 'X', 'X', 'with Tumor', 'X', 'Disease', 'Evaluation', 'Quality of Life', 'X', 'X7', 'X', 'Correlative research studies (see Section 8.0)', 'Correlative biology', 'X', 'X', '(baseline and prior to', 'cycle 3 only)', 'Tumor tissue (if available)', 'X', '1Blood chemistry and hematology assessments: must be performed at baseline, prior to each avelumab dose, at', 'end of treatment visit and at 30 days post-treatment safety follow-up.', '2Women of childbearing potential require a negative pregnancy test prior to starting treatment and must be', 'willing to adhere to effective contraceptive during and for 60 days after the last dose of avelumab. Males who', 'are sexually active with women of childbearing potential must be willing to adhere to effective contraception', 'during and for 60 days after the last dose of avelumab. Abstinence is an acceptable method of birth control.', '3Free T4 and TSH must be performed at baseline and at least every 8 weeks during treatment and at end of', 'treatment or 30 days post-treatment safety follow-up (if not performed in the previous 8 weeks)', '4 MRI of primary tumor and CT or MRI of all non-primary lesions meeting eligibility criteria. Use the same', 'imaging modality for all disease evaluations. AP and lateral radiographs should be obtained of the primary', 'tumor (if present) as well as any skeletal metastases.', '5CT of the chest is required for all patients to assess for the development of progressive pulmonary disease.', '6 18F-FDG PET/PET-CT or bone scan is required with each disease evaluation. It is recommended to obtain MRI', 'or', 'CT scan on any positive bone lesion on 18F-FDG PET/PET-CT or bone scan. Investigators are encouraged to use', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 40 of 60', 'the same modality used at baseline to follow positive lesions that are identified with 18F-FDG PET/PET-CT or', 'bone scan', '7QOL questionnaires will be completed at baseline, at the end of cycle 2 (8 weeks + lweek), at the end of cycle 4', '(16 weeks + 1week) and at the end of avelumab therapy.', '7.2', 'Extended Safety Follow-up', 'Given the potential risk for delayed immune-related toxicities, safety', 'follow-up must be performed up to 90 days after the last dose of', 'avelumab administration.', 'The extended safety follow-up beyond 30 days after last study drug', 'administration may be performed either via a site visit or via a telephone', 'call with subsequent site visit requested in case any concerns noted', 'during the telephone call.', '8.0', 'CORRELATIVE RESEARCH STUDIES', '8.1', 'Tumor Tissue', 'All patients enrolling on this protocol require institutional histological', 'confirmation of osteosarcoma at the time of original diagnosis. Even', 'though biopsy to confirm recurrence is strongly encouraged, histologic', 'confirmation of recurrence/relapse is NOT required for inclusion in this', 'study. For patients who have available tissue from diagnosis/recurrence,', 'submission of tissue for biologic studies is strongly encouraged.', 'Tumor tissue that becomes available for biological studies will be', 'processed into single cell suspensions. Purification of tumor-associated', 'lymphocytes will be performed by Percoll gradient centrifugation and', 'then frozen in appropriate freezing media or directly sorted for', 'lymphocyte analyses (described below).', '8.2', 'Immunologic Research - NCI Testing Battery', 'All patients 18 years of age and older will have 6 (10ml) green top tubes', 'and 2 (7ml) SST and patients less than 18 years of age will have 2 (10ml)', 'green top tubes and 1 (7ml) SST.', 'See Laboratory Manual for additional information on collection, processing', 'and shipment of samples.', 'Timing: prior to start of therapy and prior to starting Cycle 3.', 'Blood samples may be used for other research studies, which may include', 'phenotypic and functional analysis of immune cell subsets, circulating', 'tumor cell evaluation, and analysis for cytokines, chemokines, antibodies,', 'tumor-associated antigens and / or other markers.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}